Arkolith/Insider Trading/YMAB/Form 4

Wilms Joris

SVP & CHIEF OPERATING OFFICERY-mAbs Therapeutics, Inc. (YMAB) · full profile →Form 4 · filed Sep 18, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
13
2 non-derivative · 11 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 16, 2025Tender(U)13K$8.60$110K0
Sep 16, 2025Disposed to issuer(D)39K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 16, 2025Disposed to issuer(D)20K——0
Sep 16, 2025Disposed to issuer(D)32K——0
Sep 16, 2025Disposed to issuer(D)20K——0
Sep 16, 2025Disposed to issuer(D)36K——0
Sep 16, 2025Disposed to issuer(D)32K——0
Sep 16, 2025Disposed to issuer(D)36K——0
Sep 16, 2025Disposed to issuer(D)43K——0
Sep 16, 2025Disposed to issuer(D)20K——0
Sep 16, 2025Disposed to issuer(D)20K——0
Sep 16, 2025Disposed to issuer(D)20K——0
Sep 16, 2025Disposed to issuer(D)20K——0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001753231-25-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML